Search | Clinical Trials Finder

Conditions: Schizophrenia
Interventions: xanomeline and trospium chloride (X/T) therapy; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 20
States / cities: Costa Mesa, California • San Jose, California • Miami, Florida + 17 more

Conditions: Schizophrenia
Interventions: KarXT (xanomeline and trospium); Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 6,876 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Psychosis Associated With Alzheimer's Disease
Interventions: KarXT, Placebo; Drug
Lead sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Industry
Eligibility: 55 Years to 90 Years
Enrollment: 410 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 59
States / cities: Homewood, Alabama • Phoenix, Arizona • Encino, California + 38 more

Conditions: Cocaine Use Disorder (CUD)
Interventions: Cobenfy, Placebo; Drug
Lead sponsor: Joshua A. Lile, Ph.D.; Other
Eligibility: 18 Years to 60 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Alzheimer's Disease
Interventions: Xanomeline/Trospium Chloride Capsule, Xanomeline Enteric Capsule, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 55 Years to 90 Years
Enrollment: 426 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 42
States / cities: Chandler, Arizona • Garden Grove, California • Long Beach, California + 35 more

Conditions: Alzheimer Disease, Psychosis
Interventions: KarXT, KarX-EC, KarXT + KarX-EC Arm Matching Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 55 Years to 90 Years
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 6
States / cities: Gilbert, Arizona • Chino, California • Naples, Florida + 2 more

Conditions: Schizophrenia
Interventions: Xanomeline and trospium chloride (KarXT); Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 55
States / cities: Bryant, Arkansas • Anaheim, California • Chino, California + 44 more

Conditions: Healthy Volunteers
Interventions: Xanomeline/Trospium Chloride, Lithium, Valproic Acid, Lamotrigine; Drug
Lead sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 133 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Los Alamitos, California

Conditions: Healthy Volunteers
Interventions: Xanomeline/trospium chloride; Drug
Lead sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Schizophrenia
Interventions: Xanomeline/trospium chloride; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 13
States / cities: Little Rock, Arkansas • Bellflower, California • Garden Grove, California + 9 more

Conditions: Irritability Associated With Autism Spectrum Disorder
Interventions: KarXT, KarX-EC, KarXT + KarX-EC Matching Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 29
States / cities: Dothan, Alabama • Phoenix, Arizona • Anaheim, California + 25 more

Conditions: Schizophrenia
Interventions: Xanomeline and Trospium Chloride Capsules; Drug
Lead sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 566 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 116
States / cities: Little Rock, Arkansas • Rogers, Arkansas • Anaheim, California + 56 more

Conditions: Schizophrenia
Interventions: xanomeline-trospium chloride, Oral antipsychotics; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Suwanee, Georgia

Conditions: Schizophrenia Disorders
Interventions: Xanomeline and Trospium Chloride; Drug
Lead sponsor: Collaborative Neuroscience Research, LLC; Network
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 7
States / cities: Bellflower, California • Garden Grove, California • Riverside, California + 4 more

Conditions: Schizophrenia
Interventions: Xanomeline and Trospium Chloride Capsules, Placebo; Drug
Lead sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 79
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 61 more

Conditions: Healthy Volunteers
Interventions: KarXT, Trimethobenzamide, Ondansetron, Meclizine; Drug
Lead sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 225 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 4
States / cities: Los Alamitos, California • Hollywood, Florida • Atlanta, Georgia + 1 more

Conditions: Schizophrenia
Interventions: Xanomeline/Trospium; Drug
Lead sponsor: Vanguard Research Group; Other
Eligibility: 18 Years to 40 Years
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Richmond, Texas

Conditions: Bipolar Disorder Type I With Mania or Mania With Mixed Features
Interventions: KarXT, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 28
States / cities: Little Rock, Arkansas • Rogers, Arkansas • Culver City, California + 23 more

Conditions: Schizophrenia
Interventions: Xanomeline and Trospium Chloride Capsules; Drug
Lead sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 56
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 44 more

Conditions: Healthy Volunteers
Interventions: Xanomeline/ Trospium Chloride; Drug
Lead sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: Anaheim, California • Lenexa, Kansas • San Antonio, Texas

Conditions: Psychosis Associated With Alzheimer's Disease
Interventions: KarXT, Placebo; Drug
Lead sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Industry
Eligibility: 55 Years to 90 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 70
States / cities: Chandler, Arizona • Phoenix, Arizona • Anaheim, California + 43 more

Conditions: Bipolar-I Disorder With Mania or Mania With Mixed Features
Interventions: KarXT, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 23
States / cities: Bentonville, Arkansas • Little Rock, Arkansas • Anaheim, California + 19 more

Conditions: Schizophrenia
Interventions: Xanomeline and Trospium Chloride Capsules, Placebo Capsules; Drug
Lead sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 12
States / cities: Little Rock, Arkansas • Lemon Grove, California • Long Beach, California + 9 more

Conditions: Schizophrenia
Interventions: Xanomeline and Trospium Chloride Capsules; Drug
Lead sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 34
States / cities: Bentonville, Arkansas • Little Rock, Arkansas • Anaheim, California + 27 more

Search by objective public record fields.

Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)

Real-world Patient Characteristics, Treatment Patterns, and Healthcare Utilization Among KarXT Users

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)

The Impact of Cobenfy Maintenance on Cocaine's Effects

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease

A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)

Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)

A Study to Evaluate the Effects of Lithium, Valproic Acid, and Lamotrigine on the Pharmacokinetics of KarXT and Effects of KarXT on the Pharmacokinetics of Lithium, Valproic Acid, and Lamotrigine in Healthy Participants

KarXT Concentrations in the Breast Milk and Plasma of Lactating Females

A Study to Evaluate the Effect of KarXT on Urological Safety

A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism

An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)

Long-Term Real-World Safety of Cobenfy in Adults With Schizophrenia

An 8-week Open-label Study of an Accelerated and Slower Switching to Xanomeline/Trospium Following Atypical Antipsychotic Treatment in Participants With Schizophrenia

A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

Study to Assess Safety and Tolerability of KarXT With Administration of Antiemetics in Healthy Volunteers

An Open-Label Study to Evaluate the Efficacy and Tolerability of Xanomeline/Trospium In First Episode/Early Phase Schizophrenia Patients

A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)

An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

A Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy Adult Participants

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)

A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder

A Study to Assess Safety and Efficacy of KarXT in Adult Patients With Schizophrenia

An Extension Study to Assess Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-4)